Pfizer Back To “Business As Normal”

Nov 16, 2018

For Immediate Release
November 16, 2018
Contact: Lauren Blair
(201) 213-5004
[email protected]



Pfizer Back To “Business As Normal”
Drug Company Announces Price Hikes In Friday News Dump


Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued the following statement after Pfizer announced it will increase the list prices of 41 drugs in January:

“Pfizer can try to bury the announcement of 41 drug price hikes in a Friday news dump — but it can’t hide the real-world impact on millions of patients who are about to see the price of their medications go up. Right before the holiday season, hardworking families will now be forced to re-evaluate budgets for next year. It didn’t take Pfizer long to go back to ‘business as normal’ after making a big show of pausing price hikes earlier this year. Business as normal may be good for Pfizer’s bottom line, but it’s not good for hardworking Americans.

“This proves once again pharmaceutical companies can’t be expected to do the right thing. It will be up to Congress and President Trump to hold them accountable through bipartisan, market-based solutions.”